iZafe Group (IZAFE-B.ST) Stock Analysis & AI Equity Report
iZafe Group (IZAFE-B.ST) overview
iZafe Group (IZAFE-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, iZafe Group reported revenue of SEK 8.0m and operating profit of SEK -19.4m; the year-end share price was 0.21 SEK and market capitalisation was SEK 59.0m. iZafe Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get iZafe Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-29. Data will be refreshed during report generation.
About iZafe Group
iZafe Group AB develops and markets digital medical solutions for safer medication management at home. Its main products are the Dosell medication dispenser and the Pilloxa smart pillbox platform, which support dose administration, reminders, and patient data capture. The company sells through partners to households, healthcare providers, and pharmaceutical customers in Sweden and other markets.
Generate the iZafe Group report
iZafe Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for iZafe Group and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.